A significant proportion of patients with inflammatory bowel disease (IBD) have steroid-resistant or steroid-dependent disease that requires treatment with biologic agents. However, even when biologic therapies are used, a significant proportion of patients have primary nonresponse or develop secondary loss of response. Potential reasons for this medically resistant disease include mechanistic challenges or inadequate exposure, either owing to underdosing or secondary to loss of serum protein, including monoclonal antibody therapies, through an inflamed gut. 1 Novel strategies that overcome these challenges are needed.
The calcineurin inhibitors tacrolimus and cyclosporin have shown short-term efficacy in Crohn's disease (CD) and ulcerative colitis (UC), are fast-acting, and may be an option in treatment-refractory patients. 2, 3 In UC, cyclosporin has been used successfully as a rapidly acting bridge to the slower-acting immunomodulators in immunomodulatory-naive patients with short-term response rates in acute severe UC of greater than 80%. 2 In CD, reports of rapid response to intravenous (IV) and oral cyclosporin also have been reported with response rates up to 59%. 4, 5 Tacrolimus also shows excellent short-term efficacy in IBD with short-term response rates of 61% to 96% in UC, 6 and partial and complete response rates of 39% and 29% in CD. 7 However, despite this evidence, protracted use of calcineurin inhibitors is limited by adverse events including infection, nephrotoxicity, hypercholesterolemia, and hypertension, and long-term prognosis is poor with high relapse rates on cessation of therapy. 4, 6, 8 Consequently, their use traditionally has been limited in IBD owing to a lack of an appropriate maintenance therapy.
Vedolizumab, a monoclonal antibody to a 4 b 7 integrin that blocks lymphocyte trafficking to gut mucosa, 9 is approved for use in moderate-severe CD and UC and has efficacy in inducing and maintaining remission in both in placebo-controlled trials. 10, 11 However, improvement in clinical symptoms may be slow, with increasing response and remission rates shown at least over the course of the first 10 weeks. [10] [11] [12] Accordingly, the US prescribing guidelines suggest a minimum of 14 weeks of therapy before clinicians evaluate its efficacy. In addition, as observed with other monoclonal antibodies, 1 vedolizumab treatment in patients with severe disease theoretically is associated with increased drug loss and lower drug levels owing to protein loss via a leaky gut and, hence, reduced response may be associated with more severe disease. Indeed, patients with severe disease are at increased risk of failing biological therapy. 13 The use of combination therapy in patients with IBD commenced on biologic therapies, most commonly achieved by using immunomodulator and anti-tumor necrosis factor (TNF) therapy, is associated with increased remission rates, increased anti-TNF drug levels, and reduced loss of response. 14, 15 There are reports of patients with IBD tolerating concomitant anti-TNF and low doses of tacrolimus after liver transplant for primary sclerosing cholangitis. 16 However, because the combined immunosuppressive properties at therapeutic doses of these 2 agents can lead to adverse events including death, 17 concomitant administration to induce disease remission has been discouraged.
Because vedolizumab has impressive safety data, we hypothesized that combination therapy with a calcineurin inhibitor would not pose the same risks as combination therapy with a calcineurin inhibitor and (systemically active) anti-TNF agent. However, patients with exposure to calcineurin inhibitors were excluded from vedolizumab clinical trials and the success and safety of inducing remission and bridging from a calcineurin inhibitor to vedolizumab in IBD remains unknown. This study aimed to assess the short-and long-term responses, remission, steroid-free remission, and adverse event rates in patients treated concomitantly with a calcineurin inhibitor and vedolizumab, using prospectively collected data.
Methods

Study Design
Patients with established IBD who commenced vedolizumab at The University of Chicago Medicine Inflammatory Bowel Disease Center were invited to be included in the prospective University of Chicago Vedolizumab Database, part of the larger University of Chicago IBD Research Database. Among consenting patients, baseline patient and disease characteristics were recorded, and patient outcomes were evaluated prospectively at weeks 14, 30, and 52 of vedolizumab treatment. Clinical remission and response rates were assessed with the Harvey-Bradshaw Index (HBI) 18 for CD patients and the Simple Clinical Colitis Activity Index (SCCAI) for UC patients. 19 We performed a subanalysis on patients who commenced vedolizumab treatment between its US Food and Drug Administration approval (May 20, 2014) and March 30, 2015, who received concomitant calcineurin inhibitors during the first 12 months of vedolizumab therapy. Patients were eligible if they had a confirmed clinical, endoscopic, or histologic diagnosis of CD or UC, had at least 3 months of follow-up evaluation after commencement of concurrent calcineurin inhibitor and vedolizumab therapy, and were followed up for 12 months from their first vedolizumab infusion.
Calcineurin inhibitors were commenced at the discretion of the primary treating physician in patients with refractory IBD. These included patients with severely active UC or CD despite high-dose oral or IV prednisolone and/or anti-TNF therapy, patients with 
Intervention
Standard protocols for calcineurin inhibitor therapy induction dosing were used. Tacrolimus was initiated at 0.05 mg/kg twice daily. Dosage was adjusted according to trough level, aiming for a blood concentration of 10 to 15 ng/mL, clinical response and side effects. Trough levels, blood counts, and renal and liver profiles were measured 48 hours after treatment initiation, 1 to 2 weeks later, and every 2 to 3 weeks until steady-state trough levels were reached, after which laboratory data were checked monthly. Cyclosporin was administered intravenously at an initial dose of 2 mg/kg/d. Serum cyclosporin concentrations were measured every other day and dose was adjusted to a target level of 300 to 400 ng/mL. Intravenous therapy was continued for 5 to 7 days (up to 14 days) with dose adjustments based on C-reactive protein level, clinical symptoms, blood pressure, and renal function. Transition to oral therapy was performed when patients had improved clinical disease activity. Oral therapy was commenced at double the IV dose and was adjusted to reach similar trough concentrations as IV therapy. Outpatient cyclosporin levels, renal function, and liver function were monitored weekly.
All patients initiating calcineurin inhibitors received trimethoprim/sulfamethoxazole 800 mg/160 mg 3 times weekly for prophylaxis against Pneumocystis jirovecii. This was continued while patients remained on combination treatment with corticosteroids.
Calcineurin inhibitors were weaned after at least 6 weeks of therapy in patients who achieved clinical remission and, at the discretion of the primary treating physician, in patients who had significant clinical improvement. The initial calcineurin inhibitor dose was decreased by 50% for 2 weeks before discontinuation.
All patients received 300 mg of vedolizumab intravenously at weeks 0, 2, and 6, with maintenance dosing every 8 weeks thereafter as per standard-of-care guidelines and according to the Food and Drug Administration-approved dosing regimen for IBD. In patients commencing a calcineurin inhibitor as the induction agent, the first dose of vedolizumab was administered after initiation of calcineurin therapy.
Steroids were weaned at the discretion of the physician and baseline immunomodulators were continued throughout the study period.
Outcomes
Clinical remission was defined as HBI 4 or SCCAI 2, clinical response was defined as a reduction of 3 points in the HBI or SCCAI, and steroid-free clinical remission was defined as clinical remission without concomitant systemic corticosteroids.
When available, the endoscopic response was assessed using the Short Endoscopic Score 20 for CD patients or the Mayo endoscopic subscore 21 for UC patients after 3 months treatment with vedolizumab. Mucosal healing (MH) was defined by Short Endoscopic Score for CD score of <3 or resolution of all ulcers in CD, and in UC as a Mayo endoscopic subscore of 0/1.
At each visit patients were questioned about adverse events including infections, infusion reactions, or other potential adverse events related to vedolizumab. Adverse events were graded as serious if they resulted in antibiotic treatment, discontinuation of vedolizumab, or hospitalization.
Statistical Methods
Patients were analyzed on an intent-to-treat basis and cessation of vedolizumab for any reason was considered treatment failure. For patients who withdrew prematurely, the last observation was carried forward. Descriptive statistics were summarized using medians and interquartile ranges or means and SD and/or SEM for continuous variables. Categoric variables were expressed as a percentage and number of cohort. Univariate analysis was conducted using the chi-square or the Fisher exact tests for equal proportion. The Wilcoxon rank-sum test was used where appropriate. Pretreatment and post-treatment clinical activity scores were compared using the paired t test. A 2-sided P value .05 was considered statistically significant. All data analyses were performed using Stata 12.0 (Stata Corp, College Station, TX).
Results
Of 31 patients who required concomitant tacrolimus or cyclosporin within the first 12 months of initiating vedolizumab therapy, 27 were included in the final analysis: 2 were excluded because they were on tacrolimus secondary to liver transplant and 2 were excluded because of inadequate documentation/follow-up evaluation ( Figure 1 ). Baseline characteristics and indications for vedolizumab are shown in Table 1 . A total of 96% (n ¼ 26) failed therapy with at least 1 anti-TNF agent previously.
Co-induction With Vedolizumab and a Calcineurin Inhibitor
A calcineurin inhibitor was initiated before or at the time of commencing vedolizumab in 9 patients with CD (5 tacrolimus, 4 cyclosporin) and 11 patients with UC (4 tacrolimus, 7 cyclosporin). Fifteen patients (9 CD and 6 UC) were hospitalized at induction and failed intravenous steroids requiring salvage therapy with a calcineurin inhibitor (10 intravenous cyclosporine, 5 tacrolimus). The median duration of hospital admission was 10 days (IQR, 7-12 d). Patients commenced vedolizumab at a median of 30 days (IQR, 19-77 d) after their first dose of calcineurin inhibitor. All patients ceased the calcineurin inhibitor at 12 months. The average duration of combination therapy with a calcineurin inhibitor and vedolizumab was a median of 64 days (IQR, 42-87 d).
Crohn's Disease
As shown in Figure 2A , 67% (n ¼ 6), 67% (n ¼ 6), and 33% (n ¼ 3) of 9 patients with CD had a clinical response, and 5, 4, and 3 of 9 patients achieved remission at weeks 14, 30, and 52, respectively. A total of 67% (n ¼ 6) of patients weaned from calcineurin inhibitors by week 14, of whom 2 achieved calcineurin inhibitor-free clinical remission. Four patients were still on calcineurin inhibitors at week 30, 1 of whom had recommenced tacrolimus at week 14 after worsening disease activity after cessation at week 10. This patient eventually proceeded to surgery for treatment of refractory disease. By week 52 all patients were off calcineurin inhibitors. Thus, calcineurin inhibitor-free remission was achieved in 33% of patients at week 52.
All 9 CD patients were on prednisolone at baseline at a median dose of 40 mg/d (IQR, 20-50 mg/d). A total of 67% (n ¼ 6), 67% (n ¼ 6), and 100% (n ¼ 9) were steroid-free and 4, 4, and 3 of 9 were in steroid-free clinical remission at weeks 14, 30, and 52, respectively.
The mean HBI significantly improved from a baseline score of 11.6 (SEM, 2.0) to 5.7 (SEM, 2.3) at week 14 (P ¼ .020), and remained stable at 6.6 (SEM, 2.2) at week 30 and at 6.7 (SEM, 2.2) at week 52 (P ¼ .020) ( Figure 2B ). In patients still on vedolizumab, the mean HBI was 3.0 (SEM, 1.29) at 12 months.
Ulcerative Colitis
As shown in Figure 2C , clinical response was achieved in 73% (n ¼ 8), 82% (n ¼ 9), and 64% (n ¼ 7), and clinical remission was achieved in 55% (n ¼ 6), 45% (n ¼ 5), and 45% (n ¼ 5) at weeks 14, 30, and 52, respectively. A total of 55% (n ¼ 6) of patients were weaned from calcineurin inhibitors by week 14. Only 1 patient remained on a calcineurin inhibitor at week 30 and all patients were off calcineurin inhibitors by week 52. Thus, calcineurin inhibitor-free remission was achieved in 45% at week 52.
A total of 55% (n ¼ 6) of patients were on corticosteroids at baseline at a median dose of 40 mg/d (IQR, 25-50 mg/d). Of these, 100% (n ¼ 6), 83% (n ¼ 5), and 100% (n ¼ 6) were steroid-free, but only 2, 0, and 2 were in steroid-free clinical remission at weeks 14, 30, and 52, respectively. Overall steroid-free remission was achieved in 55% (n ¼ 6), 36% (n ¼ 4), and 45% (n ¼ 5) at weeks 14, 30, and 52, respectively.
The mean SCCAI decreased significantly from 8.2 (SEM, 0.82) at baseline to 2.0 (SEM, 0.65) at week 14 (P < .001), and then remained stable at 2.6 (SEM, 0.62) at week 30 and 1.8 (SEM, 0.58) at week 52 ( Figure 2D ). In patients still on vedolizumab, the mean SCCAI was 1.6 (SEM, 1.4) at 12 months.
Mucosal Healing After Co-induction
Of patients with a baseline and postinduction endoscopic assessment at a median of 5 months (range, 3-9 mo), MH was achieved in 1 of 7 with CD and in 4 of 7 with UC. Week 52 response rates were higher when MH was achieved (100% clinical response if MH was achieved vs 11% if no MH was achieved; P ¼ .003) and week 52 steroid-free remission rates trended higher with MH (75% steroid-free remission if MH was achieved vs 25% if no MH was achieved; P ¼ .052). MH was associated with vedolizumab continuation (100% vedolizumab continuation if MH was achieved vs 33% if no MH was achieved; P ¼ .016).
Calcineurin Inhibitor Use in Patients Failing Induction With Vedolizumab
Seven patients (5 CD and 2 UC) commenced calcineurin inhibitor therapy after primary nonresponse to vedolizumab immunotherapy. Three patients (2 UC and 1 CD) commenced within 3 months of initiating vedolizumab. Two UC patients were hospitalized for IV corticosteroids and cyclosporin in the setting of clinical symptoms despite 40 mg prednisolone and vedolizumab for 3 months. One patient failed induction therapy with cyclosporin and proceeded to colectomy. The other patient weaned from cyclosporin after 51 days and remained in steroid-and calcineurin-free clinical remission at 12 months.
Tacrolimus salvage therapy was used in 5 patients with CD; 1 at 3 months and 4 at 6 months of vedolizumab therapy. All patients were steroid-dependent, 3 patients were on vedolizumab every 4 weeks and 2 patients required hospitalization for IV steroids with failure to achieve remission. One patient was changed to vedolizumab every 4 weeks at the time of commencing tacrolimus.
The mean duration of tacrolimus was 85 days (SD, 53 d). Of the 5 CD patients, 2 achieved steroid-and calcineurin inhibitor-free remission at 12 months and continued vedolizumab. One patient continued to have disease activity at 12 months despite tacrolimus and proceeded to loop ileostomy with no complications, with subsequent maintenance with vedolizumab monotherapy. Two patients ceased vedolizumab: 1 patient did not respond to tacrolimus and had a surgical resection, and the other patient ceased for inability to wean from tacrolimus despite response.
Vedolizumab Discontinuation and Adverse Events
Vedolizumab was discontinued for nonresponse after a median of 6 months (IQR, 6-7 mo) in 41% of patients (7 CD and 4 UC). Three patients with CD and 2 with UC were switched to a different therapeutic agent, and 6 patients proceeded to surgery with 4 colectomies (2 UC and 2 CD), 1 ileal resection (CD), and 1 diverting stoma (CD). There were no intraoperative complications. Postoperatively, 1 patient had delayed perineal healing after total proctocolectomy and 1 developed a mucocutaneous separation of the stoma, which subsequently healed with antibiotics. There were no other surgical complications.
Adverse events are summarized in Table 2 . In addition to postoperative complications, there were 3 serious events in 2 patients. One patient described an infusionrelated reaction with mild swelling of the tongue. This patient had severely active disease, tested positive for Clostridium difficile and cytomegalovirus colitis with inclusion bodies on colon biopsy, ceased therapy, and proceeded to a colectomy. One patient developed viral gastroenteritis that required hospitalization, but recovered with conservative management. Side effects possibly attributed to calcineurin inhibitor toxicity were minimal. One patient discontinued tacrolimus after 1 month owing to gum sensitivity, which resolved after tacrolimus cessation. Additional side effects that did not result in discontinuation included tremor (n ¼ 2), migraine (n ¼ 1), paresthesia (n ¼ 1), leg cramps (n ¼ 1), and fatigue (n ¼ 1).
Discussion
In this prospective observational study, we show the efficacy and safety of a novel treatment approach for some patients with IBD: use of a calcineurin inhibitor in conjunction with vedolizumab. This strategy provides new options for many different clinical scenarios including failed corticosteroid therapy, failed or intolerance to thiopurine therapy, and hospitalized adults with severe IBD in whom we are concerned for gut loss of protein-based therapies and inadequate exposure. Calcineurin-based treatment also provides an induction option as a bridge to vedolizumab, to overcome the slower onset of action described for this biologic agent.
We show that using a combination of tacrolimus or cyclosporin with vedolizumab in patients with active IBD achieves steroid-and calcineurin inhibitor-free clinical remission in more than one third of patients at 1 year. The strategy also was effective when the induction therapy was introduced to patients who had failed vedolizumab monotherapy. Similar to previous reports of calcineurin inhibitor induction for UC and CD, 2,3 high initial response and remission rates were observed. Although these rates decreased over the follow-up period, 33% of CD and 45% of UC patients were in steroid-free remission at 1 year, which is similar to rates seen in the pivotal vedolizumab trials GEMINI 1 and 2, 10,11 despite the fact that this patient cohort likely represents a more treatment-resistant group. In addition, SCCAI and HBI scores improved significantly by week 14 in both CD and UC, and this improvement was maintained over 52 weeks despite patients ceasing corticosteroids and the calcineurin inhibitor. In fact, in our patient cohort, all patients who continued on vedolizumab were off corticosteroids and calcineurin inhibitors by 12 months. This suggests that calcineurin inhibitor therapy may be used as a bridge to vedolizumab in patients with moderately to severely active disease as well as a steroid-sparing therapy.
Endoscopically, 1 of 7 CD and 4 of 7 UC patients achieved MH. For UC, this is comparable with the results of the pivotal GEMINI 1 trial, which showed MH rates in initial responders of 54% in maintenance. 10 The pivotal GEMINI 2 trials for CD did not report on MH, but a realworld study showed a higher rate of 30% for MH. 22 MH was associated with continuation of vedolizumab (P ¼ .016) and week 52 steroid-free remission rates trended higher when MH was achieved (P ¼ .052). These findings support those from the anti-TNF clinical trials regarding the positive prognostic role that MH has after induction treatment on longer-term outcomes and are similar to the findings reported with standard vedolizumab therapy. 23 All patients in our study were treatment-refractory and almost all had previously failed anti-TNF therapy.
On this basis, it would be anticipated that few patients would have responded to re-induction therapy with standard anti-TNF therapy, but proof that the strategy of calcineurin inhibitors bridging to vedolizumab is more efficacious than re-treatment with a drug that had previously failed can be addressed definitively only by a randomized controlled trial. Whether such a study is ethical is dubious.
In patients who have primary nonresponse to vedolizumab monotherapy, despite adequate time for onset of action, a short duration of therapy with calcineurin inhibitors successfully salvaged patients who continued vedolizumab. At 6 months after calcineurin inhibitor salvage, 3 of 7 patients achieved steroid-free and calcineurin inhibitor-free clinical remission. Although the follow-up period was short, treatment options were limited in this patient cohort. These results therefore are promising and suggest that calcineurin inhibitor salvage may be a strategy to induce remission in this patient cohort, although clearly longer-term studies are required to determine the durability of this response. The mechanism of this response is not clear but there may be synergy of the different anti-inflammatory mechanisms of action or simply an additive benefit, followed by a more durable response to vedolizumab.
One hazard of multi-agent immunomodulator therapy in patients with IBD has been infection and other adverse events related to profound immune suppression. 8, 24 In fact, combination therapy with a calcineurin inhibitor and anti-TNF therapy has been relatively contraindicated owing to severe infection risk and even mortality. 17 However, the predominantly gut-selective effect of vedolizumab on immune reactivity and minimal side effects and infection risk associated with its use as a monotherapy may imply that the addition of a systemically acting agent with broad immune-suppressing effects would not carry infective and other complications greater than that of the individual drugs. Indeed, no significant toxicity was observed in our series despite the fact that many patients were on quadruple immunosuppressive therapy, at least initially.
The major shortcoming of our study was the small sample size, which makes it more difficult to detect uncommon adverse effects and to define predictors of response to vedolizumab. In addition, despite the prospective nature of the study, some data were missing from patients. Finally, when vedolizumab first received regulatory approval in May 2014, many patients with very complex disease received it as end-of-the-line salvage therapy at our referral center. Therefore, this patient group most likely represents a population with more severe disease than might normally be placed on this therapy in the general community.
In conclusion, this study describes a novel treatment regimen for patients with moderate to severe UC or CD, and one that may be particularly useful in patients who are steroid-refractory or who have already failed an anti-TNF treatment. Cyclosporin and tacrolimus successfully and rapidly induced response and remission in both CD and UC. We propose that this strategy can act as a bridge to maintenance vedolizumab treatment when applied to vedolizumab initiation or when there has been primary nonresponse to vedolizumab. On long-term follow-up evaluation, vedolizumab was able to maintain remission in 30% to 45% of IBD patients without the requirements for steroids or continuing the calcineurin inhibitor. Larger studies using short-term calcineurin inhibitors in conjunction with vedolizumab are warranted and planned.
